Go Pro
→ How Long Does $2.5M Last in Retirement? (From SmartAsset) (Ad)tc pixel
NASDAQ:KZIA

Novogen Q2 2026 Earnings Report

Novogen logo
$12.16 -0.45 (-3.57%)
As of 09/3/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Novogen EPS Results

Actual EPS
-$1.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
$4.89 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novogen Announcement Details

Quarter
Q2 2026
Date
2/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Novogen's next earnings date is estimated for Friday, September 4, 2026, based on past reporting schedules.

Conference Call Resources

Novogen Earnings Headlines

Novogen (NASDAQ:KZIA) Stock Price Expected to Rise, BTIG Research Analyst Says
September 3 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30999839
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1 at 7:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy-302865533.html
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply got in before the Macintosh launch. Tech analyst George Gilder says a similar setup is forming today, but instead of one company, he points to three that he calls the Trillion Dollar Triangle. Gilder argues these three companies represent connected pieces of one major shift rather than competitors racing for the same outcome.tc pixel
 |  Eagle Publishing (Ad)
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1 at 7:15 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hrher2--breast-cancer-supported-by-preclinical-data-showing-strong-clinical-activity-and-safety-in-hr-breast-cancer-302865460.html
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-limited-announces-oversubscribed-closing-of-up-to-120-million-public-offering-302865390.html
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data
August 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4941623-kazia-therapeutics-stock-worth-speculating-paxalisib-tnbc-data
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA) (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research.

Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.

View Novogen Profile
Earnings Tools